MARC Record from harvard_bibliographic_metadata

LEADER: 03491nam a2200409 a 4500
001 009234936-6
005 20090513162113.0
008 030730s2004 njua b 001 0 eng
010 $a 2003017231
020 $a1588290832 (alk. paper)
035 0 $aocm52814637
040 $aDNLM/DLC$cDLC
042 $apcc
050 00 $aRM340$b.A566 2003
060 0 $aW1$bME9616JM v.93 2003
060 10 $aQZ 170$bA629 2003
082 00 $a615/.718$222
245 00 $aAnticoagulants, antiplatelets, and thrombolytics /$cedited by Shaker A. Mousa.
260 $aTotowa, N.J. :$bHumana Press,$cc2004.
300 $ax, 307 p. :$bill. ;$c24 cm.
440 0 $aMethods in molecular medicine ;$v93
504 $aIncludes bibliographical references and index.
505 0 $aHighlights of latest advances in antithrombotics / S.A. Mousa -- Antiplatelet, anticoagulant, and thrombolytic drug interactions / O. Iqbal and S.A. Mousa -- Evaluation of platelet antagonists in in vitro flow models of thrombosis / O.J. McCarty ... [et al.] -- Heparin and low molecular weight heparin in thrombosis, cancer, and inflammatory diseases / S.A. Mousa -- Are low molecular weight heparins the same? / S.A. Mousa -- Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia / W.P. Jeske and J.M. Walenga -- Laboratory methods for heparin-induced thrombocytopenia / M. Prechel, W.P. Jeske and J.M. Walenga -- Factor Xa inhibitors / J.M. Walenga ... [et al.] -- Tissue factor/VIIa in thrombosis and cancer / S.A. Mousa -- Tissue factor pathway inhibitor in thrombosis and beyond / S.A. Mousa ... [et al.] -- Cell adhesion molecules: potential therapeutic and diagnostic implications / S.A. Mousa -- Development and applications of animal models of thrombosis / R.J. Shebuski ... [et al.] -- A survey of venous thrombosis models / W.P. Jeske ... [et al.] -- Arixtra (fondaparinux sodium) / S.A. Mousa -- Oral thrombin inhibitor ximelagatran / S.A. Mousa -- Pharmacogenomics and coagulation disorders / O. Iqbal -- Guidelines for diagnosis and treatment of deep venous thrombosis and pulmonary embolism / H. Abdel-Razeq ... [et al.].
520 $aProvides an update on various clinically relevant in vitro and in vivo models of thrombosis and haemostasis. The editor goes further to provide highlights of the novel usage of low molecular weight heparins, newer application of GPIIb/IIIa antagonists, asprin and clopidogrel, and expanded usage of polytherapeutic approaches. The book provided a contemporary look at progress achieved during the past decade In the development of newer drugs to treat thrombotic and cardiovascular diseases. This reference explains the process of establishing these newer treatments as well as reviewing all the aspects and defining the clinically relevant models for the discovery of newer generation antithrombotics. The chapters embody a manual for hematologists, pharmacologists, vascular, and cardiovascular specialists, to use in their daily practice.
650 0 $aAnticoagulants (Medicine)
650 0 $aBlood platelets.
650 0 $aThrombolytic therapy.
650 0 $aFibrinolytic agents.
650 12 $aThrombolytic Therapy$xmethods.
650 12 $aAnticoagulants$xtherapeutic use.
650 22 $aFibrinolytic Agents$xtherapeutic use.
650 22 $aHeparin$xtherapeutic use.
650 22 $aPlatelet Aggregation Inhibitors$xtherapeutic use.
650 22 $aThrombocytopenia$xdrug therapy.
700 1 $aMousa, Shaker A.
988 $a20031112
906 $0OCLC